Onconetix, Inc. Files S-1/A Amendment
Ticker: ONCO · Form: S-1/A · Filed: Jun 5, 2024 · CIK: 1782107
Sentiment: neutral
Topics: sec-filing, s-1/a, pharmaceuticals
TL;DR
Onconetix (fka Blue Water Biotech) filed S-1/A amendment. IPO incoming?
AI Summary
Onconetix, Inc. filed an S-1/A amendment on June 4, 2024, for its registration statement. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. The filing details its principal executive offices located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio.
Why It Matters
This filing is a step in the process for Onconetix, Inc. to potentially offer its securities to the public, which could impact its funding and future operations.
Risk Assessment
Risk Level: medium — As an S-1/A filing, it indicates a company is preparing to go public or has recently done so, which carries inherent market and execution risks.
Key Numbers
- 333-277066 — SEC File Number (Identifies the specific registration statement)
- 20240604 — Filing Date (Date of the amendment filing)
Key Players & Entities
- Onconetix, Inc. (company) — Registrant
- Blue Water Biotech, Inc. (company) — Former company name
- Blue Water Vaccines Inc. (company) — Former company name
- 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio (location) — Principal executive offices
- Bruce Harmon (person) — Chief Financial Officer
FAQ
What is the purpose of this S-1/A filing?
This S-1/A filing is an amendment to Onconetix, Inc.'s registration statement, indicating updates or revisions to its initial filing for securities offerings.
What were Onconetix, Inc.'s previous names?
Onconetix, Inc. was formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc.
Where are Onconetix, Inc.'s principal executive offices located?
The principal executive offices of Onconetix, Inc. are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio.
What is the SIC code for Onconetix, Inc.?
The Standard Industrial Classification (SIC) code for Onconetix, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Who is listed as the Chief Financial Officer?
Bruce Harmon is listed as the Chief Financial Officer.
Filing Stats: 4,515 words · 18 min read · ~15 pages · Grade level 15.8 · Accepted 2024-06-04 20:35:06
Key Financial Figures
- $0.00001 — e "Company," or "Onconetix"), par value $0.00001 per share (the "Common Stock"), by the
- $1.09 — ducement PIOs have an exercise price of $1.09 per share and will expire five years fr
- $1.3625 — ducement PIOs have an exercise price of $1.3625 per share and will expire five years fr
- $2.546 — he Sabby PIOs have an exercise price of $2.546 per share and will expire five years fr
- $0.238 — sdaq Capital Market on May 30, 2024 was $0.238 per share. We recommend that you obtain
Filing Documents
- ea0203788-s1a2_onconetix.htm (S-1/A) — 4483KB
- ea020378801ex10-60_onconetix.htm (EX-10.60) — 83KB
- ea020378801ex10-61_onconetix.htm (EX-10.61) — 61KB
- ea020378801ex10-62_onconetix.htm (EX-10.62) — 17KB
- ea020378801ex23-1_onconetix.htm (EX-23.1) — 2KB
- ea020378801ex23-2_onconetix.htm (EX-23.2) — 2KB
- ea020378801ex23-3_onconetix.htm (EX-23.3) — 5KB
- image_001.jpg (GRAPHIC) — 4KB
- image_002.jpg (GRAPHIC) — 25KB
- image_003.jpg (GRAPHIC) — 17KB
- image_004.jpg (GRAPHIC) — 14KB
- image_005.jpg (GRAPHIC) — 465KB
- image_006.jpg (GRAPHIC) — 362KB
- ex10-61_001.jpg (GRAPHIC) — 8KB
- ex10-62_001.jpg (GRAPHIC) — 3KB
- ex10-62_002.jpg (GRAPHIC) — 8KB
- ex23-3_001.jpg (GRAPHIC) — 6KB
- 0001213900-24-049815.txt ( ) — 19740KB
- onco-20240331.xsd (EX-101.SCH) — 141KB
- onco-20240331_cal.xml (EX-101.CAL) — 130KB
- onco-20240331_def.xml (EX-101.DEF) — 806KB
- onco-20240331_lab.xml (EX-101.LAB) — 1216KB
- onco-20240331_pre.xml (EX-101.PRE) — 826KB
- ea0203788-s1a2_onconetix_htm.xml (XML) — 2026KB
USE OF PROCEEDS
USE OF PROCEEDS 53 DETERMINATION OF OFFERING PRICE 54 ABOUT THE COMPANY 55 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION 98 ONCONETIX'S MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 103 PROTEOMEDIX MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 119 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 148
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 149 SELLING STOCKHOLDERS 153 PLAN OF DISTRIBUTION 155 EXPERTS 156 LEGAL MATTERS 156 WHERE YOU CAN FIND MORE INFORMATION 156 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") using a "shelf" registration process for the delayed or continuous offering and sale of securities pursuant to Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"). This prospectus generally describes Onconetix, Inc. and our Common Stock. The Selling Stockholders may use the shelf registration statement to sell up to an aggregate of up to 7,828,812 shares of our Common Stock from time to time through any means described in the section entitled " Plan of Distribution ." We will not receive any proceeds from the sale of shares of Common Stock to be offered by the Selling Stockholders pursuant to this prospectus. However, we will pay the expenses, other than underwriting discounts and commissions, associated with the sale of shares pursuant to this prospectus. We and the Selling Stockholders, as applicable, may deliver a prospectus supplement with this prospectus, to the extent appropriate, to update the information contained in this prospectus. The prospectus supplement may also add, update or change information included in this prospectus. You should read both this prospectus and any applicable prospectus supplement, together with additional information described below under the captions " Where You Can Find More Information " and " Incorporation of Certain Information by Reference ." No offer of these securities will be made in any jurisdiction where the offer is not permitted. You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free writing prospectus